J. Heart Lung Transplant., 1999, v. 18, p. 611-626.

Противопоказания к трансплантации сердца

злоупотребление алкоголем

психические заболевания

злокачественные новообразования

неконтролируемые хронические инфекционные процессы

выраженная печеночная либо почечная (клиренс креатинина < 50 мл/мин или креатинин плазмы > 250 ммоль/мл) недостаточность

стойкое повышение легочно-сосудистого сопротивления (транспульмональный градиент > 15 мм рт. ст., систолическое давление в легочной артерии > 60 ммНд)

недавно перенесенные тромбоэмболические осложнения

открытая пептическая язва

другие заболевания, характеризующие плохим прогнозом

невозможность надлежащего наблюдения пациента

Список литературы

1. Амосова Е.Н. Желудочковые нарушения ритма и
внезапная смерть при застойной сердечной
недостаточности: перспективы модификации исхода
заболевания с помощью амиодарона//Укр.кард.журнал. -
1995.-№4.-с.78-84.

2. Беленков Ю.Н., Агеев Ф.Т., Мареев В.Ю. Нейрогормоны и
цитокины при сердечной недостаточности: новая терапия
старого заболевания? // Сердечная недостаточность.-
2000.-№4.-с. 1-6.

3. Воронков Л.Г., Коваленко В.Н., Рябенко Д.В. Хроническая
сердечная недостаточность: механизмы, стандарты
диагностики и лечения/ Киев, Морион.-1999.-128 с.

4. Воронков Л.Г. Патогенез и клиническая диагностика
хронической сердечной недостаточности // Doctor-2001.-N
4(8).-с.12-18.

5. Дзяк Г.В., Дриновец И., Васильева Л.И., Ханюков А.А.
Недостаточность кровообращения. Методическое пособие
в таблицах и схемах. - Днепропетровск, 1999, 270 с.

6. Дядык А.А., Багрий А.Э. Современные представления о
патофизиологии сердечной недостаточности. Часть I.
Интракардиальные нарушения // Укр.терапевт. журнал.-
2ОО1.-т.З.-№ 1.-с. 69-74.

7. Киричек Л.Т., Самохвалов В.Г. Вегетативная нервная
сисетма: структурно-функциональные особенности и
фармакологическая регуляция. /Харьков., 1993. - 78 с.

8. Малая Л.Т., Горб Ю.Г., Рачинский И.Д. Хроническая

недостаточность кровообращения / К., Здоров'я, 1994. -624 с.

9. Малая Л.Т. Новое в лечении хронической
недостаточности кровообращения // Укр.терапевт. журнал.-
2ОО1.-т.З.-№1.-с.5-16.

10. Мареев И.Ю. Сердечная недостаточность и
желудочковые нарушения ритма сердца: Кардиология. -
1996.-№12.-С.4- 12.

11. Меерсон Ф.З. Адаптация, дезадаптация и
недостаточность сердца / М., Москва, 1978. - 343 с.

12. Сидоренко Б.А., Преображенский Д.В., Алексеева Л.А. и
др. Хроническая сердечная недостаточность с сохраненной
систолической функцией левого желудочка:
распространенность, этиология, течение и прогноз (обзор
литературы и результаты собственных исследований) //
Укр.терапевт. журнал.-2001.-т.З.-№ 1.- с. 28 - 33.

13. Рабочая группа по сердечной недостаточности
Украинского научного общества кардиологов. Лечение
больных с сердечной недостаточностью: Инструкция для
врача-практика // Doctor-2001.-N 4 (8).-с.52-55.

14. Ткаченко М.М. Оксид азоту та судинна регулящя //
Журнал АМН Укра1ни.-1997.-т.З.-№ 2.-С.241-254.

15. АСС / AHA Guidelines for the Evaluation and Management
of Chronic Heart Failure in the Adult. A report of the American
College of Cardiology / American Heart Association Task Force
on Practice Guidelines. 2001, by the American College of

Cardiology and the American Heart Association, Inc.- 55 p.

16. Adamopoulos S., Parissis J.T., Kremastinos D.T. A glossary
of circulating cytokines in chronic heart failure // Europ. Heart.
Failure.-2001.-V.3.- p.517-526.

17. AIRE: The Acute Infarction Ramipril Efficacy (AIRE) study
investigators. Effect of ramipril on mortality and morbidity of
survivors in acute myocardial infarction with clinical evidence of
heart failure//Lancet- 1993. -v. 342. - p. 821 -828.

18. Anker S.D., Ponikowski P.P., Clark A.L et al. Cytokines and
neurohormones relating to body composition alterations in the
wasting syndrome of chronic heart failure // European Heart J.-
1999.-V.20.-P.683-693.

19. Anker S.D., Rauchhaus M. Heart failure as a metabolic prob
lem//Europ. J. Heart Failure. - 1999. - v. 1. - p. 127 - 131.

20. Aukrust P., Ueland Т., Lien E. etal. Cytokine network in con
gestive heart failure secondary to ischemic or idiopathic dilated
cardiomyopathy// Amer. J. Cardiol.- 1999.-V. 83.- p.376-382.

21. Benedict C.R., Johnstone D.E., Weiner D.H. et al. Relation
of neurohormonal activation to clinical variables and degree of
ventricular dysfunction: a report from the registry of studies of
left ventricular dysfunction//J. Amer. Coll. Cardiol.-1994.-v.23.-
p.1410-1420.

22. Berry C, Clark A.L. Catabolism in chronic heart failure //
Europ. J. Heart Failure.-2000.-v.21.-p.521-532.

23. Bonet S., August M.A., Arnau J.U. et al. Beta-adrenergic
blocking agents in heart failure: benefits of vasodilating and
non-vasodilating agents according to patients' characteristics: a
meta-analysis of clinical trials//Arch.Intern.Med.-2000.-v. 160.-
p.621-627.

24. BristowM.R., Hershberger RE., Port J.D. etal. β-adrenergic
pathways in nonfailing and failing human ventricular myocardi
um//Circulation.- 1990.-V. 82.(Suppl I).-1 12-1 25.

25. Brater D.C. Diuretic theraphy// N. Eng.J.Med.- 1998.-V.
339.- p.387 - 395.

26. BroddeO-E. p1 -and P2 - adrenoreceptors in human heart:
properties, function, and alterations in chronic heart failure. //
Pharmacol. Rev.- 1991. - v.43. - p.202-242.

27. Burnier M., Brunner H.R. Angiotensin II receptor antagonists
// Lancet.- 2000.-v.355.-p.637-645.

28. Cazeau S, Leclerc C, Lavergne N. et al. Effects of multisite
biventricular pacing in patients with heart failure and intraven
tricular conduction delay// N. Eng. J. Med.- 2001.-v. 344.-
p.873 - 880.

29. Ceconi G., Feuerstein G. Oxidative stress links cytokine
activation with apoptosis / In. Heart Failure: New Goals, New
Guidelines. Ed.: Remme W.J. - SKB Publ., 1997.-p.4-6.

30. Cheng C.R, Onishi K., Onte N. et al. Functional effects of
endogenous bradykinin in congestive heart failure //J.Amer.
Coll.Cardiol.- 1998.-V.31.-p. 1679-1686.

31. CIBIS-II Investigators and Committees. The cardiac
insuffiency bisoprolol Study II (CIBIS-II): a randomised trial //
Lancet.- 1999.-v.353.-p.9-13.

32. Clark A.L, Poole-Wilson P.A., Coats A.I.S. Exercise limitafion
in chronic heart failure: the central role of the periphery // J/
Amer. Cardiol. - 1996. - v.28. - p. 1092-1102.

33. Cleland J.G.F., Witte K., Thackray S. Bradykinin and ventric
ular function // Europ. Heart. J. -Suppl.- 2000.-v.2.-(Suppl H).-
p.H20-H29.

34. Cohn J.N., Levine В., Olivari M.T. et al. Plasma norepineph
rine as a guide to prognosis in patients with chronic congestive
heart failure//N. Engl. J. Med. - 1984. -v. 311. - p. 819 - 823.

35. Cohen-Solal A. Role of aldosterone in heart failure. // Europ
Heart. J. Suppl.- 2000. -v. 2., Suppl. A.-p. A 17 - A 20.

36. Colucci W.S. The sympathetic nervous system in congestive
heart failure/In: Congestive Heart Failure. Eds. Hosenpud J.D.,
Greenberg B.H.- New York, Springer-Verlag.-1994.-p.126-135.

37. Comini L, Bachetti Т., Angoletti L. etal. Induction of func
tional inducible nitric oxide synthase in monocytes of patients
with congestive heart failure. Link with tumour necrosis factor -
a//Europ. Heart J.-1999.-V.20.- p. 1503-1513.

38. Congestive Heart Failure. Pathophysiology, Diagnosis and
Comprehensive Approach to Management/ Eds.: Hosenpud
J.D., Creenberg B.H.- Springer-Verlag New York.-1994.- 769 p.

39. Cook S.A., Poole-Wilson PA. Cardiac myocyte apoptosis //
Europ. Heart. J. -1999.-v.20.-p. 1619-1629.

40. Cowburn P.J., Cleland J.G., Coats A.J., Kimajda M. Risk
stratification in chronic heart failure // Europ. Heart J. - 1998. -
v. 19.-p. 696-710.

41. Cowburn P.J., Cleland J.G F. Endothelin antagonists for
chronic heart failure: do they have a role? // Europ. Heart. J.-
2001.-v. 19.- p.1772-1784.

42. Cowie M.R., Wood D.A., Coats A. et al. Survival of patienrs
with new diagnosis of heart failure: a population based study //
Heart.-2000.-v.83.-p.505-510.

43. Depre C, Davies P.J.L., Taegtmeyer H. Transcriptional
adaptation of the heart to mechanical unloading // Amer. J.

Cardiol.- 1999.-vol.83.-p.58 H-63 H.

44. Ferguson D., Berg W., Roach P. et al. Effects of heart failure
on baroreflex control of sympathetic neural activity //
Amer.J.Cardiol.-1992.-v.69.-p.523-531.

45. Ferrari R., Bachetti Т., Agnoletti L. et al. Endothelial function
and dysfunction heart failure // Europ. Heart J.-1998.-v. 19
(Suppl.G), G41 - G47.

46. Feuerstein G.S., Puffolo R.R. Carvedilol, a novel vasodilating
beta-blocker with the potential for cardiovascular organ protec
tion // Europ. Heart. J.- 1996.-V. 17, Suppl.В: p. 24 - 29.

47. Feurestein G.S., Poste G., Ruffolo R.R. Carvedilol update III:
rationale for use in congestive heart failure // Drugs of Today. -
1995.-V.31.-p.307-326

48. Francis G.S., Cohn J.N., Johnson G. et al. Plasma norepi
nephrine, plasma renin activity and congestive heart failure.
Relations of survival and the effects of therapy in V-He FT II. The
V-He FT Cooperative Studies Group // Circulation.- 1993.- v.87
(Suppl XI): p. 140- 148.

49. Fruhwald F.M., Fahrleitner A., Watzinger N. etal. N-terminal
proatrial natriuretic peptide correlates with systolic dysfunction
and left ventricular filling pattern in patients with idiopathic dilat
ed cardiomyopathy// Heart.- 1999.-v.82.- p.603-1109.

50. Gilbert E.M., Olsen S.L, Renlund D.G., Bristow M.R. Beta-
adrenergic receptor regulation and left ventricular function in
idiopathic dilated cardiomyopathy//Amer. J. Cardiol.-1993,-
v.71. (Suppl C).-p.23c-29c.

51. Gilbert E.M., Olsen S.L, Renlund D.G., Bristow M.R. Beta-
adrenergic receptor regulation and left ventricular function in
idiopathic dilated cardiomyopathy//Amer. J. Cardiol.-1993.-
V.71.-N9. - p. 23 С-29 С.

52. Grassi J., Seravalle G., Cattaneo B.U. et al. Sympathetic
activation and loss of reflex sympathetic control in mild conges
tive heart failure // Circulation.- 1995.- v.92.-p. 3206 - 3211.

53. Guidelines for the diagnosis and treatment of chronic heart
failure. Task Force for the Diagnosis and Treatment of Chronic
Heart Failure, European Society of Cardiology: W.J.Remme and
K.Swedberg (Co-Chairmen). // Europ. Heart J.-2001.-v.22.-

p. 1527-1560.

54. Hartl W.H. Effects of kinins on glucose and protein metabo
lism in vivo / In: The role of bradykinin in the cardiovascular
action of the converting enzyme inhibitor ramipril. Eds Bonner
G., Scholkens B.A., Chichester,, Media Medica.-1992.- p. 111-
117.

55. Hornig В., Arakawa N., Drexler H. Effect of ACE inhibition on
endotelial dysfunction in patients with chronic heart failure //
Europ. Heart. J. - 1998.-v.19 (Suppl. G.) - G 48 - G 53.

56. Ikeda U., Shimada K. Nitric oxide and cardiac failure // Clin
Cardiol.-1997.-v.20.-p. 837-841.

57. Katz A. Heart Failure. Pathophysiology, Molecular Biology
and Clinical Management/ Philadephia, Lippincott Williams a.
Wilkins, 2000.- 381 p.

58. Kendall M.J. Possible mechanisms of action in the positive
effect of beta-blockers in heart failure // Heart.-1999.-v. 82,
Suppl.lV: p. IV5-IV17.

59. Kupari M., Lindroos M., Jivanainen A.M. et al. Congestive
heart failure in old age; prevalence, mechanismus and 4-year
prognosis in the Helsinki Ageing Study//J.Int. Med. - 1997. - v.
241. - p. 387 - 394.

60. Levine T.B., Francis G.S., Goldsmith S. Activity of the sympa-

thetic nervous system and renin - angiotensin system assessed hormone levels and ther relationship to hemodynamic abnormalities in congestive heart failure // Amer. J. Cardiol. - 1992. -v. 49.-p. 1659- 1666.

61. Lorell B.H. Role of angiotens'n AT1 and AT2 receptors in car
diac hypertrophy and disease//Amer. J. Cardiol.- 1999.-
vol.83.-p.48 H-52 H.

62. Luchner A., Borgeson D.D., Grantham J. etal. Relationship
between left ventricular wall stress and ANP gene expression
during the evolution of rapid ventricular pacing-induced heart
failure in the dog //Europ.J. Heart Failure.- 2000.-V.2.- p.379-
386.

63. Mark A.L. Sympathetic dysregulation in heart failure: mech
anisms and therapy//Clin. Cardiol.- 1995. - v.18 (Suppl I).- p.
I3 -18.

64. Massie B.M., Abdalla I. Heart failure in patients with pre
served left ventricular systolic function: do digitalis glycosides
have a role? // Progr. Cardiovasc. Dis.- 1998.-V. 40.- p.357 -
369.

65. Me Murray J., Cohen-Solal A., Dietz R. et al. Practical rec
ommendations for the use of ACE inhibitors, beta-blockers and
spironolactone in heart failure: putting guidelines into practice
// Europ.J.Heart Failure.-2001.-v.3.-p.495-502.

66. MERIT-HF Study Group. Effect of metoprolol CR/XL in
chronic heart failure. Metoprolol CR/XL Randomised
Intervention Trial in Congestive Heart Failure (MERIT-HF) //
Lancet.- 1999.-v.353.-p.2001-2007.

67. Metra M., Giubbini R., Nodari S. et al. Differential effects of
beta-blockers in patients with heart failure: A prospective,
randomized, double-blind comparison of the long-term effects
of metoprolol versus carvedilol // Circulation, -2000.-v.102.-

p.546-551.

68. Mosterd A., Hoes A.W., de Bruyne M. C, et al. Prevalence of
heart failure left ventricular dysfunction in the general popula
tion. The Rotterdam Study. // Europ. Heart J. - 1999. - v. 20. -
p. 447 - 455.

69. Munger M.A., Furniss S.M. Angiotensin II receptor blockers:
novel therapy for heart failure // Pharmacotherapy Card. Mass. -
1996.- v. 16 (Part 2). 59 S - 68 S.

70. Neubauer S. High-energy phospate metabolism in normal,
hypertrophied and failing human myocardium// Heart Failure
Rev. - 1999. v.4. - p.269-280.

71. Nishikimi T. Adrenomedullin in cardiovascular disease // Adv.
Pharmacol.- 1998.-v. 42.- p.599-603.

72. Nogele H., Bohlann M., Eck U. et al. Combination therapy
with carvedilol and amiodarone in patients with severe heart fail
ure // Europ. J.Heart Failure.-v.2.-p.71-79.

73. O'Connel J.B., BristowM.R. Economic impact of heart fail
ure in the United States: time for a different approach //J. Heart
Lung Transplant. -1993. -v. 13. -S 107 - S 112.

74. Olivetti G., Abbi R., Quaini F. Apoptosis in the failing human
heart//N. Engl. J. Med.-1997. - v.336. - p. 1131-1141.

75. 100 years of the renin-angiotensin system. / Eds. Nicholls
M.G., Brunner H.R., Ikram H. Merk.Co Inc., Whitehouse
Station, N.J., USA, 1998.-180p.

76. Otterstad J.E., Froeland G., Sutton M., Holme I. Accuracy
and reproducibility of biplane two-dimensional echocardio
graphy measurements of left ventricular dimensions and func
tion//Europ. Heart J.- 1997.-v.18.-p.507-513.

77. Packer M., BristowM.R., Cohn J.N. etal. The effect of
carvedilol on morbidity and mortality in patients with chronic
heart failure. U.S. Carvedilol Heart Failure Study Group // N/
Engl. J. Med.- 1996.-v.334.-p. 1349-1355.

78. Packer M., Coats A.I.S., Fowler M.B. et al. for the Carvedilol
Prospective Randomise Cumulative Survival Study Group. Effect
of carvedilol on survival in severe chronic heart failure // N.Engl.
J. Med.- 2001.-v.344.-p.1651-1658.

79. Parchure N.A., Kaski J.С. Oxidant stress (reactive oxygen
species) and cardiovascular disease (part I) // Europ.
Cardiologist J.-1998.-V.3.-N 72-12/11.

80. Paulus W.J. How are cytokines activated in heart failure? //
Europ. Heart Failure.-1999.-v.L-p.309-312.

81. Pausset F, Isnard R., Lechat P. et al. Prognostic value of
plasma- endothelin -1 in patients with chronic heart failure //
Europ. Heart J.-1997.-V.18.- p.254-258.

82. Pausset F, Masson F, Chavirovskaia O. et al. Plasma
adrenomedullin, a new independent predictor of prognosis in
patients with chronic heart failure // Europ. Heart. J. -2000.-
v.21.-p.1009-1014.

83. Pfeffer M.A., Braunwald E., Moye L.A. et al. Effect of capto
pril on mortality and morbidity in patients with left ventricular
dysfunction after myocardial infarction. Results of the survival
and ventricular enlargement trial. The SAVE Investigators //
N.Engl. J. Med.- 1992,-v.327.-p.669-677.

84. Pitt В., Poole-Wilson P.A., Segal R. etal. on behalf of the
ELITE II Investigators. Effect of losartan compared with captopril
on mortality in patients with symptomatic heart failure: ran
domised trial - the Losartan Heart Failure Survival Study ELITE II
// Lancet.- 2000.-v.355.-p. 1582-1587.

85. 23. Pitt В., Segal R., Martinez F.A., et al. on behalf of ELITE
Study Investigators. Randomised trial of losartan versus capto
pril in patients over 65 with heart failure (Evaluation of Losartan
in Elderly Study ELITE)//Lancet.- 1997.-v.349.-p.747-752.

86. Pitt В., Zannad R, Remme W.J. et al. The effect of spirono
lactone on morbidity and mortality in patients with severe heart
failure// Randomized Aldactone Evaluation Study Investigators
//N.Engl. J. Med.- 1999.-v.341.-p.709-717.

87. Ponikowsky P., Banasiak W. Chemosensitivity in chronic
heart failure //Heart Failure Monitor. -2001. - v.1.- N4. - p. 126
-131

88. Rihal C.S., Davis V.B., Kennedy J.W., Gersh B.J. The utility of
clinical, echocardiographic and roentgenographic variables in
the prediction of lef ventricular function // Amer. J. Cardiol. -
1995.-v.75.-p.220-223.

89. Rose E., Gellijns A.C., Moskowitz A.J. et al. for the
REMATCH study group. Long-term use of a left ventricular assist
device for end-stage heart failure // N. Eng. J. Med.- 2001.-v.
345.-p. 1435- 1443.

90. Rosenzweig A., Seidman С Atrial natriuretic factor and
related peptide hormone// Ann. rev. Biochem.. -1991.-v.60.-
p.229-255.

91. Rostagno C, Galanti G., Felici M. et al. Prognostic value of
baroreflex sensitivity assessed by phase IV of Valsalva maneuvre
in patients with mild-to-moderate heart failure // Europ. J. Heart
Failure.-2000.-v.2.-p,41 -45.

92. Rouleau J.J.L., Pfeffer M.A., Stewart D.J. et al. Comparison
of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise
tolerance and morbidity in patients with heart failure: IMPRESS
randomised tril // Laancet.-2000.-v.356.-p.615-620.

93. Sabbah H.N., Stanley W.C. Partial fatty acid oxidation
inhibitors: a potentially new class of drugs for heart failure //
Europ. J. Heart. Failure. - 2002.-V.4. - p.3 - 6.

94. Sabbah H. The cellular and physiologic effects of beta-
blockers in heart failure//Clin.Cardiol.-1999.-v. 22, Suppl.5: p.
V16-V20.

95. Saraste A., Pulkki K., Kallajoki M.et al. Cardiomyocyte apop-
tosis and progression of heart failure to transplantation //
Eur.J.CIin. Invest.-1999.-v. 29 (5).-p.380-386.

96. Sasayama S., Matsumori A., Kihara G. et al. New insights
into the pathophysiological role for cytokines in heart failure //
Cardiovasc. Res. - 1999.-v.42.- p.557-564.

97. Singh S.N. Congestive heart failure arrhythmias: therapeutic
modalities//J. Cardiovasc-1997,-v. 8 - p. 88-97.

98. Sleight P. The renin-angiotensin system: a review of trials
with angiotensin-converting enzyme inhibitors and angiotensin
receptor blocking agents // Europ. Heart J. Suppl. -2002.- v.4.
(Suppl. 4).- p. A53-A57.

99. Spinale F.G., Coker M.L., Bond B.R., Zellner J.L Myocardial
matrix degradation and metalloproteinase activation in the fail
ing: heart a potential therapeutic target // Cardiovasc. Res. -
2000.-V.46.-P.225-238.

100. Swynghedauw В., RapaportL., Schwartz К. Heart failure
as a disease of adaptation / In: Cardiac hypertrophy and failure.
Ed. Swynghedauw B. INSERM / John Libbey Eurotext. - London
- Paris. - 1990. - p. 679-686.

101. Swynghedauw B. Myocardial effects of nitric oxide: what
should the clinician remember? // Europ. Cardiologist J.-2000.-
v.-N 2.-10.01.

102. Talwar S., Squire I.В., Davies J.E. et al. Plasma N-terminal
pro-brain natriuretic peptide and the ECG in the assessment of
left-ventricular systolic dysfunction in a high risk population //
Europ.Heart.J. - 1999.-v.20.- p.1736-1744.

103. The CONSENSUS trial study group. Effects of enalapril on
mortality in severe congestive heart failure: Results of the
Cooperative North Scandinavian Enalapril Survival Study
(CONSENSUS) // N.Engl. J. Med. - 1987. - v. 316 - p. 1429 -
1435.

104. The Digitalis Investigation Group. The effect of digoxin on
mortality and morbidity in patients with heart failure // N. Eng.
J.Med. - 1997.- v. 336. - p. 525 - 533.

105. The SOLVD investigators. Effect of enalapril on survival in
patients with reduced ejection fraction and congestive heart fail
ure. // N.Engl. J. Med. - 1991. - v. 325 - p. 293 - 302.

106. The SOLVD investigators. Effect of enalapril on mortality
and the development of heart failure in asymptomatic patients
with reduced left ventricular ejection fraction // N.Engl. J. Med.

- 1992.-v. 327-p. 685-691.

107. Torre-Amrione J., Volletich M.T., Farmer J.A. Role of
tumour necrosis factor-alpha in the progression of heart failure:
therapeutic implications// Drugs. -2000.-v.59.-p.745-751.

108.TRACE: Torp-Pe^tersen C, Kober L, Carlsen J. Angiotensin

- convertiong enzyme inhibition after myocardial infarction: the
Trandolapril Cardiac Evaluation Study //Amer Heart J. -1996. -
v. 132.-p. 235-243.

109. Tsumamoto T, Wada A., Maeda K. et al. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction // Europ.Heart.J. - 1999.-V.20.-P.1799-1807.

110. Tyagi S.C., Bheemanathini VS., Mandi D. Role of extracel
lular matrix metalloproteinases in cardiac remodeling // Heart
Failure Review.-1996.-v.L-p.73-80.

111. Ventricular remodeling and heart failure / Eds. Cohn. J.N.,
Ferrari R., Sparpe N. - London, SKB Publ., 1998. - p. 29 p.

112. Wei СМ., Lerman A.L, Rodeheffer R.J. etal. Endothelin in |
human congestive heart failure//Circulation.-1994.-v.89.-
p.1580-1586.

113. Yamasaki N. Role of renin-angiotensin system in cardiac
hypertrophy//Amer. J. Cardiol.- 1999.-vol.83.-p.53 H-57 H.

114. Yoshikawa Т., Port J.D., Asano К. et al. Cardiac adrener
gic receptor effects of carvedilol // Europ. Heart J. -1996. - v.17|
(Suppl.B). -p. 8-16.

Дата добавления: 2015-08-10